Navigation Links
DioGenix' MSPrecise Identifies Early-Stage Patients with Multiple Sclerosis
Date:11/8/2012

GAITHERSBURG, Md., Nov. 8, 2012 /PRNewswire/ -- DioGenix, Inc., a company developing molecular diagnostics for the early diagnosis and monitoring of immune-mediated neurological diseases, today announced its lead product MSPrecise™ outperformed the specificity of the current standard of care for cerebral spinal fluid (CSF) analysis in patients suspected of having multiple sclerosis (MS) by almost two to one with no loss of sensitivity. MSPrecise is a proprietary next-generation sequencing assay that analyzes changes in key genes involved in the adaptive immune system of patients being evaluated for MS. The results of this clinical study are consistent with two prior DioGenix studies, all of which compared MSPrecise results both to published performance data for the oligoclonal banding test and experimental controls.

Patients that present with clinical symptoms and evidence of inflammation and damage to the myelin sheath that surrounds and protects nerve fibers in the CNS undergo a battery of tests in a diagnostic process that can take months to years to complete. The diagnostic standard of care for MS includes CSF analysis using the oligoclonal banding test, which detects immunoglobin G proteins that indicate an immune response within the CNS. Because the oligoclonal banding test yields a high rate of false positive results, confident diagnosis also requires a comprehensive set of clinical tests including magnetic resonance imaging and, in certain cases, visual evoked potentials. Due to the variability of symptoms between patients and the lack of a definitive test, it has been estimated that the misdiagnosis rate for MS is higher than any other immune-mediated neurological disease.

"The results of our most recent study continue to support our belief that MSPrecise will be an important new tool in the management of patients suffering with MS. We have clearly demonstrated, in a series of clinical studies, the pow
'/>"/>

SOURCE DioGenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. From lectures to explosives detection: Laser pointer identifies dangerous chemicals in real-time
2. Parthenon Identifies Emerging Opportunities in Targeted Payload Cancer Therapeutics
3. Corporate Venturing and Early-Stage Financing in the Spotlight at BioTrinity
4. Access BridgeGap Ventures to Focus on Early-Stage Therapeutic Opportunities
5. Multimodal Treatment of Peritoneal Metastases Offers Hope for Many Patients With Colorectal Cancer
6. Stem Cells Bring New Hope for Parry-Romberg Syndrome Patients
7. Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year
8. Study of Cell Therapeutics Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Now Enrolling
9. Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
10. How Malignant Cells in Patients With Chronic Lymphocytic Leukemia Escape T Cell Recognition and Attack
11. Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 Reportlinker.com announces that a ... catalogue: Global Chelating Agents Market 2014-2018 ... About Chelating Agent A chelating agent is a ... metal ions, thereby forming a metal-ion complex. It ... on chemical processes, formulations, and the environment by ...
(Date:8/27/2014)... “We are honored to be named ... Thangaraj, CEO of Radiant Sage. “We are offering truly ... imaging corelab market to a different level. We ... to efficiently and effectively manage the massive amounts of ... analyzed and read by trained physicians. Being recognized by ...
(Date:8/27/2014)... -- Research and Markets has announced the ... Paper Industry Report 2014" report to their offering. ... Paper Industry Report 2014 is a professional and in-depth ... for pulp & paper industry. The report ... classifications, applications and industry chain structure. The enzyme for ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Riviera ... is announcing the creation of the Sancilio Scientific ... take the SCI’s philosophy of looking to nature ... and development actions are based on sound scientific ... Scientific Advisory Board provides a vehicle for SCI ...
Breaking Biology Technology:Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2Global Enzyme for Pulp & Paper Industry Report 2014 2New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3
... for Cancer Research (OICR) announced today it has enhanced ... called the IPDC Fund. The augmented program is designed ... stage technologies. "In the face of declining ... to offer greater support for the most promising Ontario-based ...
... Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today ... 2011 Conference on Tuesday, March 15th at 3.30 PM ... Convention Centre, Milan, Italy.Bio Europe Spring 2011CTI Presentation: Tuesday, ... AM PSTRoom Yellow 2, Milano Convention Centre (MIC) Media ...
... This release is available in German . ... which make them promising candidates for optoelectronic components. However, ... or influence their optic and electronic properties. A team ... at the Technische Universitaet Muenchen and member of the ...
Cached Biology Technology:Ontario Institute for Cancer Research Announces Enhancements to its Intellectual Property Development and Commercialization Program 2Ultra fast photodetectors out of carbon nanotubes 2
(Date:8/27/2014)... it is related to ability that we already possess. ... melody more easily than learning how to hit a ... the Neural Basis of Cognition (CNBC)a joint program between ... a fundamental constraint in the brain that may explain ... the Aug. 28, 2014, issue of Nature , ...
(Date:8/27/2014)... of Utah biologist agan Sekercioglu, who campaigns to save ... highest science prize, which is similar to the U.S. ... researchers picked for 2014 the top awards by TUBITAK, ... researchers won the Science Award and two including ... to the Science Award but for scientists who are ...
(Date:8/27/2014)... what is described by the Volunteer Wildfire Services of ... Cape provincial government warned residents in certain parts of ... veld fires. A high veld fire danger rating ... coast in the Great Kei and Mnquma area. ... thunderstorms. The thunderstorms bring lightning strikes and subsequent ...
Breaking Biology News(10 mins):Pitt and Carnegie Mellon engineers discover why learning can be difficult 2Pitt and Carnegie Mellon engineers discover why learning can be difficult 3University of Utah biologist wins Turkey's top science prize 2
... scientists have received new funding for a research program ... economically feasible. The project is based on the serendipitous ... fish cages in Puerto Rico by the thousands. The ... fascinating habits such as their tendency to crawl in ...
... mussels and oysters are important vehicles for the ... undercooked. Vibrio species, including human pathogens, are particularly ... even after cleaning procedures, thus representing a potential ... are well known to affect the persistence of ...
... during the summer in Alaska waters, is one of the ... in the 1800s has now left us with only a ... different species from right whales seen in the North Atlantic ... areas and ecological parameters critical to the survival of this ...
Cached Biology News:New project aims to make large-scale lobster farms feasible 2New project aims to make large-scale lobster farms feasible 3Edible bivalves as a source of human pathogens: signals between vibrios and the bivalve host. 2Habitat use by North Pacific right whales, Eubalaena japonica, in the Bering Sea and Gulf of Alaska 2
Mouse monoclonal [GB3] to Kalinin ( Abpromise for all tested applications). entrezGeneID: 3918 SwissProtID: Q13753...
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: